Exosla Therapeutics

Exosla Therapeutics is a private, pre-clinical stage biotech developing a novel extracellular vesicle (EV)-based immunotherapy platform. The company's technology aims to overcome historical challenges in EV manufacturing, such as batch-to-batch variability, by using EVs from specific, immortalized monoclonal MSC lines to create a standardized, scalable product. With a seasoned leadership team combining deep EV science, clinical neurology, and biopharma entrepreneurship, Exosla is positioned to advance its lead program towards clinical trials for neonatal neurological conditions while exploring broader applications in restorative medicine.

Proprietary platform for manufacturing standardized, scalable extracellular vesicles (EVs) derived from immortalized monoclonal mesenchymal stem/stromal cell (MSC) lines, designed for immune-modulation and tissue repair.

Exosla competes in the emerging extracellular vesicle therapeutics space, facing competition from other EV-focused biotechs (e.g., Codiak BioSciences, Evox Therapeutics) and developers of cell-based therapies. Its key differentiator is the use of immortalized MSC lines aimed at solving scalability and batch consistency issues.